Cognitive enhancement with methylphenidate and modafinil: conceptual advances and societal implications

References

• Smith ME, Farah MJ. Are prescription stimulants “smart pills?” The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull. 2011;137(5):717–741.
   Google Scholar
• Ragan CI, Bard I, Singh I. What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology. 2013;64:588–595.
   PubMed Web of Science ®Google Scholar
• Sahakian B, Morein-Zamir S. Professor’s little helper. Nature. 2007;450(20):1157–1159.
   Google Scholar
• Appel JM. When the boss turns pusher: a proposal for employee protections in the age of cosmetic neurology. J Med Ethics. 2008;34:616–618.
   PubMed Web of Science ®Google Scholar
• Larriviere D, Williams MA, Rizzo M, Bonnie RJ. Responding to requests from adult patients for neuroenhancements. Guidance of the Ethics, Law and Humanities Committee. Neurology. 2009;73:1406–1412.
   PubMed Web of Science ®Google Scholar
• DeSantis AD, Webb EM, Naor SW. Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. J Am Coll Health. 2008;57(3):315–323.
   PubMed Web of Science ®Google Scholar
• Dubljević V, Sattler S, Racine E. Cognitive enhancement and academic misconduct: a study exploring their frequency and relationship. Ethics Behav. 2013;24(5):408–420.
   Web of Science ®Google Scholar
• Dubljević V.. Enhancement with modafinil: benefiting for harming the society. In: Jotterand F, Dubljevic V, editors. Cogntive Enhancement: Ethical and Policy Implications in International Perspectives. Oxford, UK: Oxford University Press; 2015. In press.
   Google Scholar
• Dubljević V. Response to open peer commentaries on “prohibition or coffee shops: regulation of amphetamine and methylphenidate for enhancement use by healthy adults.” Am J Bioethics. 2014;14(1):W1–W8.
   PubMed Web of Science ®Google Scholar
• Dubljević V, Saigle V, Racine E. The rising tide of tDCS in the media and academic literature. Neuron. 2014;82(4):731–736.
   PubMed Web of Science ®Google Scholar
• US President’s Council on Bioethics. Beyond Therapy: Biotechnology and the Pursuit of Happiness. Washington, DC: US President’s Council on Bioethics; 2003.
   Google Scholar
• European Group on Ethics in Sciences and New Technologies. Opinion on the Ethical Aspects of ICT Implants in the Human Body: Opinion of the European Group on Ethics in Sciences and New Technologies to the European Commission. Vol 20. Luxembourg: Office for Official Publications of the European Communities; 2005.
   Google Scholar
• British Medical Association. Boosting Your Brainpower: Ethical Aspects of Cognitive Enhancements. A Discussion Paper from the British Medical Association [BMA]; 2007. Available from: http://enhancingresponsibility.com/wp-content/uploads/2014/01/Boosting_brainpower_tcm41-147266.pdf. Accessed June 22, 2015.
   Google Scholar
• Frauenhofer Institute. Converging Technologies and their Impact on the Social Sciences and Humanities; 2008. Available from: http://ethics.iit.edu/NanoEthicsBank/node/1843. Accessed June 22, 2015.
   Google Scholar
• JASON Advisory Group. Human Performance. JASON (Program for Office of Defense Research and Engineering) (No JSR-07-625). JASON Advisory Group for Department of Defence, Pentagon; 2008. Available from: http://www.fas.org/irp/agency/dod/jason/human.pdf. Accessed June 22, 2015.
   Google Scholar
• Science and Technology Options Assessment (STOA). Human Enhancement Study. The Hague, the Netherlands: Rathenau Institute; 2009.
   Google Scholar
• Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75(6):406–433.
   PubMed Web of Science ®Google Scholar
• Ballon JS, Feifel D. Systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67(4):554–566.
   PubMed Web of Science ®Google Scholar
• de Jongh R, Bolt I, Schermer M, Olivier B. Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci Biobehav Rev. 2008;32(4):760–776.
   PubMed Web of Science ®Google Scholar
• Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477–1502.
   PubMed Web of Science ®Google Scholar
• Kanal M, Ozkan C, Doganavsargil O, Eryilmaz M. Late onset mania due to modafinil use: a case report. Bull Clin Psychopharmacol. 2012;22(1):71–74.
   Google Scholar
• Gerrard P, Malcolm R. Mechanisms of modafinil: a review of current research. Neuropsychiatr Dis Treat. 2007;3(3):349–364.
   PubMedGoogle Scholar
• Dubljevic V. Prohibition or coffee-shops: regulation of amphetamine and methylphenidate for enhancement use by healthy adults. Am J Bioethics. 2013;13(7):23–33.
   PubMed Web of Science ®Google Scholar
• Iversen L. Speed, Ecstasy, Ritalin. The Science of Amphetamines. London, UK: Oxford University Press; 2008.
   Google Scholar
• Hysek CM, Simmler LD, Schillinger N, et al. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination. Int J Neuropsychopharmacol. 2014;17:371–381.
   PubMed Web of Science ®Google Scholar
• Bruggisser M, Bodmer M, Liechti ME. Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Swiss Med Wkly. 2011;141:w13267.
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work. Am J Psychiatry. 2005;162(10):1983.
   Web of Science ®Google Scholar
• Wu P, Jones SG, Ryan CJ, Michail D, Robinson T. Modafinil-induced psychosis. Intern Med J. 2008;38(8):677–678.
   Web of Science ®Google Scholar
• Sheng P, Hou L, Wang X, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systemic review and meta-analysis. PLoS One. 2013;8(12):e81802.
   PubMed Web of Science ®Google Scholar
• Carstairs SD, Urquhart A, Hoffman J, Clark RF, Cantrell FL. A retrospective review of supratherapeutic modafinil exposures. J Med Toxicol. 2010;6(3):307–310.
   PubMedGoogle Scholar
• Mohamed AD. Modafinil has the potential for addiction. AJOB Neurosci. 2012;3(2):36–38.
   Google Scholar
• Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain. Clinical implications. J Am Med Assoc. 2009;301(11):1148–1154.
   PubMed Web of Science ®Google Scholar
• Anonymous. Cognitive enhancement. All on the mind. The Economist. May 22, 2008.
   Google Scholar
• Greely H, Sahakian B, Harris J, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008;456(11):702–705.
   Google Scholar
• Greely HT. Law and the revolution in neuroscience: an early look at the field. Akron Law Rev. 2009;42:687–715.
   Google Scholar
• Mohamed AD, Sahakian BJ. The ethics of elective psychopharmacology. Int J Neuropsychopharmacol. 2011;15:559–571.
   Web of Science ®Google Scholar
• Repantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010;62:187–206.
   PubMed Web of Science ®Google Scholar
• Gilbert JG, Zimmer LE, Kubis JF, Donnelly KJ. Effect of magnesium pemoline and methylphenidate on memory improvement and mood in normal aging subjects. Int J Aging Human Dev. 1973;4(1):35–51.
   Web of Science ®Google Scholar
• Smith D, Pernet A, Rosenthal JM, et al. The effect of modafinil on counter-regulatory and cognitive responses to hypoglycaemia. Diabetologia. 2004;47(10):1704–1711.
   Web of Science ®Google Scholar
• Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology. 2003;168(4):455–464.
   PubMed Web of Science ®Google Scholar
• Rogers RD, Blackshaw AJ, Middleton HC, et al. Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour. Psychopharmacology. 1999;146:482–491.
   PubMed Web of Science ®Google Scholar
• Fond G, Micoulaud-Franchi JA, Macgregor A, et al. Neuroenhancement in healthy adults, part I: pharmaceutical cognitive enhancement: a systematic review. J Clin Res Bioethics. 2015;6(2):1000213.
   Google Scholar
• Kelley AM, Webb CM, Athy JR, Ley S, Gaydos S. Cogntion enhancement by modafinil: a meta-analysis. Aviat Space Environ Med. 2012;83:685–690.
   Google Scholar
• Dubljevic V. Principles of justice as the basis for public policy on psycho-pharmacological cognitive enhancement. Law Innov Technol. 2012;4(1):67–83.
   Google Scholar
• Khushf G. The use of emergent technologies for enhancing human performance: are we prepared to address the ethical and policy issues? Publ Pol Pract. 2005;4(2):1–17.
   Google Scholar
• Campa R. Pure science and the posthuman future. J Evol Technol. 2008;19(1):28–34.
   Google Scholar
• Bostrom N. Smart policy: cognitive enhancement in the public interest. In: Zonneveld L, Dijstelbloem H, Ringoir D, editors. Reshaping the Human Condition: Exploring Human Enhancement. The Hague, the Netherlands: Rathenau Institute; 2008:29–36.
   Google Scholar
• Agar N. Liberal Eugenics: In Defense of Human Enhancement. Malden, MA: Wiley-Blackwell; 2005.
   Google Scholar
• Fukuyama F. Our Posthuman Future: Consequences of the Biotechnology Revolution. New York, NY: Picador; 2002.
   Google Scholar
• Habermas J. Die Zukunft der menschlichen Natur [Future of Human Nature]. Frankfurt am Main, Germany: Suhrkamp; 2001.
   Google Scholar
• Buchanan A, Brock D, Daniels N, Wikler D. From Chance to Choice: Genetics and Justice. Cambridge, UK: Cambridge University Press; 2000.
   Google Scholar
• Parens E. Authenticity and ambivalence: toward understanding the enhancement debate. Hastings Cent Rep. 2005;35(3):34–41.
   PubMed Web of Science ®Google Scholar
• Levy N. Neuroethics. Cambridge, UK: Cambridge University Press; 2007.
   Google Scholar
• Harris J.. Chemical cognitive enhancement: is it unfair, unjust, discriminatory, or cheating for healthy adults to use smart drugs. In: Illes J, Sahakian B, editors. Oxford Handbook of Neuroethics. Oxford, UK: Oxford University Press; 2011:265–272.
   Google Scholar
• Selgelid M. An argument against arguments for enhancement. Stud Ethics Law Technol. 2007;1(1) Art. 12.
   Google Scholar
• Rawls J. A Theory of Justice – Revised Edition. Cambridge, MA: Harvard University Press; 1999.
   Google Scholar
• Glannon W. Psychopharmacological enhancement. Neuroethics. 2008;1(1):45–54.
   Web of Science ®Google Scholar
• Dubljević V. Toward a legitimate public policy on cognition-enhancement drugs. Am J Bioethics Neurosci. 2012;3(3):29–33.
   Google Scholar
• Forlini C, Racine E. Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: perspectives of key stakeholders. Neuroethics. 2009;2(3):163–177.
   Web of Science ®Google Scholar
• Dubljević V. Cognitive enhancement, rational choice and justification. Neuroethics. 2013;6(1):179–187.
   Web of Science ®Google Scholar
• Savulescu J. Justice, fairness and enhancement. Ann N Y Acad Sci. 2006;1093:321–338.
   PubMed Web of Science ®Google Scholar
• Nozick R. Anarchy, State, and Utopia. New York, NY: Basic Books; 1974.
   Google Scholar
• Miller D. Principles of Social Justice. Cambridge, MA: Harvard University Press; 1999.
   Google Scholar
• Sen A. The Idea of Justice. Cambridge, MA: Belknap Press of Harvard University Press; 2009.
   Google Scholar
• Walzer M. Spheres of Justice. New York, NY: Basic Books; 1983.
   Google Scholar
• Dubljević V. Cognitive enhancement: a glance at the future and ethical considerations. In: Knafo S, Venero C, editors. Cognitive Enhancement, Amsterdam, the Netherlands: Elsevier; 2015:343–365.
   Google Scholar
• United Nations. Convention on Psychotropic Substances, 1971. Available from: http://www.unodc.org/unodc/en/treaties/psychotropics.html. Accessed June 22, 2015.
   Google Scholar
• Jotterand F, Dubljević V, editors. Cognitive Enhancement: Ethical and Policy Implications in International Perspectives. Oxford, UK: Oxford University Press. 2015 In Press.
   Google Scholar
• Kolker R. The real limitless drug isn’t just for lifehackers anymore. New York Magazine. March 31, 2013. Available from: http://nymag.com/news/intelligencer/modafinil-2013-4/. Accessed April 2, 2013.
   Google Scholar
• DAK. Gesundheitsreport 2009. Analyse der Arbeitsunfähigkeitsdaten. Schwerpunktthema Doping am Arbeitsplatz [Healthreport 2009. Analysis of Workforcedata. Focus topic Doping in the Workplace]. Berlin, Germany: IGES; 2009.
   Google Scholar
• Schelle KJ, Faulmuller N, Caviola L, Hewstone M. Attitudes toward pharmacological cognitive enhancement – a review. Front Syst Neurosci. 2014;8:53.
   PubMedGoogle Scholar
• Partridge B, Lucke J, Hall W. A comparison of attitudes toward cognitive enhancement and legalized doping in sport in a community sample of Australian adults. Am J Bioethics Prim Res. 2012;3(4):81–86.
   Google Scholar
• Dodge T, Williams KJ, Marzell M, Turrisi R. Judging cheaters: is substance misuse viewed similarly in the athletic and academic domains? Psychol Addict Behav. 2012;26(3):678–682.
   Web of Science ®Google Scholar
• Bell S, Partridge B, Lucke J, Hall W. Australian university students’ attitudes towards the acceptability and regulation of pharmaceuticals to improve academic performance. Neuroethics. 2013;6(1):197–205.
   Web of Science ®Google Scholar
• Fitz NS, Nadler R, Manogaran P, Chong EWJ, Reiner P. Public attitudes toward cognitive enhancement. Neuroethics. 2013;7(2):173–188.
   Web of Science ®Google Scholar
• Schermer M. On the argument that enhancement is “cheating”. J Med Ethics. 2008;34(2):85–88.
   PubMed Web of Science ®Google Scholar
• Blank R. Globalization: pluralist concerns and contexts. In: Giordano J, Gordijn B, editors. Scientific and Philosophical Perspectives in Neuroethics. Cambridge, UK: Cambridge University Press; 2010:321–342.
   Google Scholar